STXS News Alert Stereotaxis (STXS) 1.42 12/13/2014 07:28:43

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stereotaxis (STXS) 1.42 $STXS

Insider Trading Alert - CODE, COV And STXS Traded By Insiders
at The Street - Tue Dec 09, 10:37AM CST
Stocks with insider trader activity include CODE, COV and STXS
COV: 100.49 (-1.36), STXS: 1.42 (unch), CODE: 31.31 (-0.11)

Stereotaxis' CEO William Mills on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:10PM CST

STXS: 1.42 (unch)

Stereotaxis Q3 EPS of -$0.10
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST

STXS: 1.42 (unch)

Stereotaxis Reports 2014 Third Quarter Financial Results
GlobeNewswire - Wed Nov 05, 3:37PM CST
-Improves System Revenue 89% Sequentially from Second Quarter 2014-
STXS: 1.42 (unch)

Stereotaxis (STXS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST

STXS: 1.42 (unch)

Stereotaxis to Report Third Quarter 2014 Financial Results on November 5, 2014
GlobeNewswire - Thu Oct 30, 3:49PM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 third quarter ended September 30, 2014 on Wednesday, November 5, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.42 (unch)

Stereotaxis Secures First Niobe(R) System Order in Japan
GlobeNewswire - Wed Sep 24, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received the first commercial order for its Niobe(R) ES magnetic navigation system in Japan from a leading hospital in Osaka. As part of its primary market strategy, the Company also announced it has established a business office in Japan under the leadership of its new Business Director, who will oversee development and operational activities, including serving as liaison with the Company's in-country distributors and other local resources.
STXS: 1.42 (unch)

Stereotaxis Receives FDA Clearance of Vdrive(TM) With V-Loop(TM) System
GlobeNewswire - Thu Sep 04, 5:35AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) to market its Vdrive(TM) Robotic Navigation System with V-Loop(TM) Variable Loop Catheter Manipulator in the U.S. The Company submitted a 510(k) Premarket Notification for the Vdrive with V-Loop system in March, following completion of a 120-patient, multi-center clinical study.
STXS: 1.42 (unch)

Stereotaxis Reports 2014 Second Quarter Financial Results
GlobeNewswire - Mon Aug 04, 3:05PM CDT
-Achieves Second Consecutive Quarter of Strong Recurring Revenue-
STXS: 1.42 (unch)

Stereotaxis to Report Second Quarter 2014 Financial Results on August 4, 2014
GlobeNewswire - Mon Jul 28, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.42 (unch)

Stereotaxis to Present Niobe(R) System Technology at Japan Heart Rhythm Society
GlobeNewswire - Mon Jul 21, 6:09AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will present at the 29 Annual Meeting of the Japanese Heart Rhythm Society in Tokyo beginning July 23, 2014. The three-day event is the first large-scale opportunity for the Company's in-country distributors, Medix Japan, Inc. and Hokushin Medical Co. Ltd., to promote the clinical value of the Stereotaxis Niobe(R) Magnetic Navigation System for cardiac ablations to the Japan electrophysiology (EP) market. Stereotaxis entered into an agreement with the two medical device distributors in February 2014 to market, sell and distribute the Niobe system and disposable devices to Japanese customers.
STXS: 1.42 (unch)

Stereotaxis to Highlight Efficiency, Efficacy and Safety of Its Technology at Cardiostim 2014
GlobeNewswire - Mon Jun 16, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will participate in Cardiostim 2014, the biennial scientific congress of the European Heart Rhythm Association (EHRA), to be held June 18-21, 2014 in Nice, France. The event represents the largest conference attended by the Company in Europe, expected to draw more than 5,600 electrophysiology (EP) and cardiology professionals from Europe and around the world.
STXS: 1.42 (unch)

Stereotaxis Submits 510(k) Application to FDA for Vdrive(TM) with V-Loop(TM) System
GlobeNewswire - Tue Apr 01, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has submitted a 510(k) Premarket Notification with the Food and Drug Administration (FDA) for the Company's Vdrive(TM) Robotic Navigation System with V-Loop(TM) Variable Loop Catheter Manipulator. This submission includes both the single arm system (Vdrive) and the two arm system (Vdrive Duo). If cleared by the FDA, the Vdrive with V-Loop system will be the Company's second Vdrive product to be cleared for use in the U.S. Its Vdrive with V-Sono(TM) Intracardiac Echocardiography Catheter Manipulator received FDA clearance in July 2013 and has been utilized in more than 75 cardiac ablation procedures to date in North America.
STXS: 1.42 (unch)

Stereotaxis Expands Credit Facility With Silicon Valley Bank to $10 Million
GlobeNewswire - Mon Mar 31, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into an amended credit agreement with Silicon Valley Bank (SVB) that replaces its existing $3 million revolving facility with a $10 million revolving facility scheduled to mature on March 31, 2015.
STXS: 1.42 (unch)

Improved Stock Price Performance of HealthCare Related Companies - Research Report on Omega, BioScrip, Accuray, Stereotaxis and Sagent Pharmaceuticals
PR Newswire - Fri Dec 20, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Omega Healthcare Investors Inc. (NYSE: OHI), BioScrip Inc. (NASDAQ: BIOS), Accuray Incorporated (NASDAQ: ARAY), Stereotaxis Inc. (NASDAQ: STXS), and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
OHI: 38.96 (+0.38), SGNT: 27.85 (-0.65), BIOS: 5.91 (-0.12), JWN: 74.65 (+0.46), ARAY: 6.95 (+0.04), STXS: 1.42 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 41

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 92

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 114

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Sunrise New Energy Unveils Innovative Solid-State Battery Patent

Updated Category News Views 205

Sunrise New Energy's Patent for Solid-State Battery Innovation Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) has made significant strides in energy technology with the announcement of a groundbreaking invention patent for a novel method of creating lithium cerate-coated graphite iron oxide anode material. This development is a significant leap forward in the realm of...

Continue Reading
Leadership Transition at Lykos Therapeutics Following FDA Setback

Updated Category News Views 103

Leadership Change at Lykos Therapeutics After FDA Setback Amy Emerson has resigned as CEO of Lykos Therapeutics following significant regulatory hurdles. This change comes after the Food and Drug Administration (FDA) recently rejected the company's application for its ecstasy-based therapy aimed at treating post-traumatic stress disorder (PTSD). Consequences of FDA...

Continue Reading
RADCOM to Showcase Innovations at Upcoming Growth Conference

Updated Category News Views 228

RADCOM to Showcase Innovations at Growth Conference RADCOM Ltd. (Nasdaq: RDCM) is gearing up for a prominent appearance at the 28th Annual Needham Growth Conference. The conference will take place at the esteemed Lotte NY Palace Hotel, where the company is excited to highlight its cutting-edge technological advancements. Leadership Team Participation At this significant...

Continue Reading
Shoppers Prioritize Savings Over Convenience, Survey Reveals

Updated Category News Views 81

New Insights into Consumer Preferences During Holidays A recent survey conducted by GoDaddy sheds light on the evolving preferences of consumers as the holiday season approaches. The findings reveal that convenience often takes a backseat to cost savings, which fundamentally impacts how businesses engage with their customers. The Importance of Cost Savings According to...

Continue Reading
Criteo's Insider Trading Insights: What You Need to Know

Updated Category News Views 116

Understanding Recent Insider Trading at Criteo Recently, significant insider trading activity has caught the attention of investors and analysts. Notably, Ryan Damon, Chief Legal Officer at Criteo, made headlines with a prominent stock sale involving his holdings in the company. Insider Sales: A Breakdown During a recent filing, it was disclosed that Ryan Damon sold 3,393...

Continue Reading